Belgian Biotech Celyad Targets $99M US IPO
Belgium-listed Celyad SA fine-tuned plans Monday to draw roughly $99.4 million in a U.S. initial public offering and a concurrent private placement, marking the latest European biotech to list abroad as...To view the full article, register now.
Already a subscriber? Click here to view full article